Therefore,
Reimbursement efluelda fluad vaccines:
For 65 and over.Toa55 / iStock / Getty Images Plus / via Getty Images
Résumé
EFLUELDA and FLUAD vaccines are now refundable in the city (65 % or 100 % during the vaccination campaign period) and approved to communities for influenza prevention in people 65 and over.
These vaccines have a specific formulation. In addition, their use in the elderly aims to compensate for the reduction of the vaccination response:
- Efluelda is a high dose trivalent vaccine;
- Fluad is a vaccine containing an adjuvant.
In April 2025, the High Authority for Health (HAS) recommended preferentially using these two vaccines in people 65 and over. Meanwhile, This population is the most exposed to the serious forms of flu causing hospitalization or death. Nevertheless, Within this reimbursement efluelda fluad vaccines group. However, the HAS notes that people living in healthcare establishments (EHPAD or USLD) and people 75 and over benefit from the additional effect of high -dose or adjuvan vaccines, by comparison with standard vaccines.
Sanofi (EFLUELDA). For example, Seqirus (FLUAD) laboratories have confirmed that orders are open for the provision of these vaccines in October 2025, during the next seasonal flu vaccination campaign. Therefore,
Lthe vaccines against the seasonal flu Efluelda and Fluad were registered on the list of reimbursable specialties and that of the specialties approved to the communities [1, 2]in the following indication:
Two specific formulations to strengthen vaccination efficiency in the elderly
EFLUELDA and FLUAD vaccines are inactivated trivalent vaccines containing two A -strain antigens and a B strain antigen, in accordance with the recommendations of the World Health Organization (WHO):
- A/Victoria/4897/2022 (H1N1)pdm09-souche analogue ;
- A/Croatia/10136RV/2023 (H3N2)-souche analogue ;
- B/Austria/1359417-Suching.
reimbursement efluelda fluad vaccines

.
Compared to standard trivalent vaccines, they have a specific formulation aimed at compensating for the decrease in the vaccine response (immunostenscence) in the elderly:
- Efluelda is a highly dosed in influenza antigens: a dose of 0.5 ml includes 60 micrograms of hemagglutinin for each antigen. against 15 micrograms in standard formulations;
- Fluad contains an adjuvant, the MF59C (Squalène, polysorbate 80, sorbitane trioleate, sodium citrate and citric acid).

.
According to their marketing authorization (AMM), Efluelda and Fluad are both indicated for active immunization in the prevention of flu, but in different age populations:
- 60 years and more for Efluelda;
- 50 years and over for Fluad.
These vaccines should be used on the basis of official recommendations on flu vaccination.
HAS recommendations for the 2025-2026 campaign
In April 2025 [3]the High Authority for Health (HAS) specified the reimbursement efluelda fluad vaccines place of these two vaccines in the vaccination strategy. After analysis of efficiency data (cf. Framed 1). epidemiological, it recommends the preferential (and equivalent) use of these two formulations in people 65 and over, compared to standard dose vaccines without adjuvant.
French epidemiological data show that people 65. over support the heaviest burden in terms of hospitalization, death or decompensation of comorbidities.
|
The HAS has evaluated the relative vaccination efficiency (EVR) of high -dose vaccines and vaccines adjuvanted in relation to standard vaccines (quadrivalents and trivalents) based on the following criteria:

. reimbursement efluelda fluad vaccines
For the two types of vaccines, the HAS notes a heterogeneity of the EVR estimates with non -significant results, regardless of the judgment criterion. However. it notes an EVR in favor of adjuvanted or high dose vaccines compared to standard vaccines in the majority of studies analyzed. 
. |
Among people aged 65 and over, HAS identifies two subpopulations more at risk of exposure, severe forms of flu or death [4] :
- Resident subjects in accommodation establishments for dependent elderly people (EHPAD) and long -term care units (USLD): due to the high age -related impact of residents (75 % of 75 and over) and community life that increases the risk of transmission;
- Subjects aged 75 and over: due to the strong impact of flu in this population, particularly in terms of mortality (74 to 85 % of the deaths attributable to flu occurs reimbursement efluelda fluad vaccines in subjects aged 65 and over).

.
In these two groups, the effect of a high dose (EFLUELDA) or adjuvan (FLUAD) vaccine provides benefit from a standard vaccine.
In people 65 and over, the HAS recalls that the objective is to reach vaccination coverage of at least 75 %.
Reimbursement efluelda fluad vaccines
Some practical information
Efluelda and Fluad appear in pre -filled syringe containing a dose of vaccine (0.5 ml).
The injectable suspension is ready for use. It is advisable to wave the syringe with injection.
The injection needle is provided.
The injection of EFLUELDA and FLUAD is carried out by intramuscular route, in the deltoid. Additionally,
The Sanofi. Seqirus laboratories have confirmed that orders for these vaccines are open, for provision during the Vaccination 2025-2026 campaign:
- Contact wholesalers for Efluelda;
- Contact Seqirus customer service directly for Fluad.
Administrative identity
Efluelda suspension in 0.5 ml pre -filled syringe with separate needle, unit box, CIP 3400930305010
Fluad Injectable suspension in 0.5 ml pre -filled syringe with needle, unit box, CIP 3440930304716
Repayable at 65 % (cf. Framed 2) [1] and 100 % as part of the annual vaccine campaign
Prix public TTC = 23,97 euros [5]
Approval for communities (cf. Framed 2) [2]
Sanofi Winthrop Industry (EFLUELDA) and VIFOR France (FLUAD) laboratories
|
Further reading: [Rétro] The earth pear, a tuber vegetable that makes its hole – Visit of a “gendered” health center, reserved for women, a safe place for patients and doctors – There are 2 brands of rosé wine not to buy according to 60 million consumers – In Marseille, the Luminy campus soon ready to accommodate biotech chips | The doctor’s daily life | Medical news – Funding for the AIDS fighting program preserved before the US Senate vote on Trump Cups.
